

ASX Announcement 3 September 2020

CEO bonus payment

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announces that Regeneus CEO and Executive Director Leo Lee has received a one-off cash bonus payment of \$325K (inclusive of all tax and withholdings) from the Company, following the signing of the licence and collaboration agreement with Kyocera Corporation.

This one-off bonus payment has been determined by the Regeneus Board based on the completion of execution of the agreement between Regeneus and Kyocera for the commercialisation of the Company's lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis in Japan (as announced on 11 August 2020), and the subsequent upfront payment of 100M JPY (~A\$1.3M) received from Kyocera (as announced on 28 August 2020). Regeneus expects a further US\$4M from Kyocera in October 2020.

The upfront, development and regulatory milestone payments from Kyocera totals to US\$19M (A\$27M). In addition, there are single to high double-digit royalties on Progenza OA sales in Japan based on future reimbursement prices.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com